{
    "title": "MIDAS UPDATE: Snakebite antidote maker BTG is worth holding on to",
    "url": "https://www.dailymail.co.uk/money/investing/article-2384101/MIDAS-UPDATE-Snakebite-antidote-maker-BTG-worth-holding-to.html",
    "date": "2013-08-03",
    "keywords": [
        "btg",
        "company",
        "growth",
        "year",
        "profit",
        "market",
        "btgs",
        "maker",
        "executive",
        "louise",
        "turnover",
        "treatment",
        "share",
        "online",
        "medicine",
        "business",
        "cent",
        "division",
        "group",
        "liver",
        "cancer",
        "antidote",
        "mail",
        "sunday",
        "gmt",
        "september",
        "email",
        "view",
        "glaxosmithkline",
        "expansion",
        "programme",
        "city",
        "fan",
        "base",
        "midas",
        "december",
        "price",
        "potential",
        "operating",
        "remedy",
        "firm",
        "series",
        "line",
        "glaxo",
        "cap",
        "summer",
        "rush",
        "season",
        "flatfee",
        "dividend",
        "sign",
        "fund",
        "supermarket",
        "commission",
        "specialty",
        "licensing",
        "biotechnology",
        "cash",
        "part",
        "prostate",
        "makin",
        "week",
        "institute",
        "health",
        "excellence",
        "number",
        "pipeline",
        "varicose",
        "blood",
        "confidence",
        "today",
        "challenge",
        "yachtswoman",
        "weekend",
        "gruelling",
        "race",
        "whole",
        "focus",
        "healthcare",
        "asia",
        "drive",
        "europe",
        "bank",
        "stock",
        "value",
        "ticker",
        "contact"
    ],
    "category": [
        "money",
        "investing"
    ]
}